Hypoxia-induced matrix metalloproteinase-13 expression in astrocytes enhances permeability of brain endothelial cells

Journal of Cellular Physiology

Volumn 220, Issue 1, 2009, Pages 163-173

  Lu, Dah Yuu ^a,b   Yu, Wei Hsuan ^b   Yeh, Wei Lan ^b   Tang, Chih Hsin ^a   Leung, Yuk Man ^a   Wong, Kar Lok ^a   Chen, Yuh Fung ^a   Lai, Chih Ho ^c   Fu, Wen Mei ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COLLAGENASE 3; MESSENGER RNA; PROTEIN C FOS; PROTEIN C JUN; PROTEIN ZO1; MEMBRANE PROTEIN; MMP13 PROTEIN, RAT; PHOSPHOPROTEIN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; ZONULA OCCLUDENS 1 PROTEIN; ZONULA OCCLUDENS-1 PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; ENDOTHELIUM CELL; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROKE; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; CELL CULTURE; CELL HYPOXIA; CULTURE MEDIUM; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEWBORN; RNA INTERFERENCE; SPRAGUE DAWLEY RAT; TIGHT JUNCTION; TIME; VASCULARIZATION;

RATTUS;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELL HYPOXIA; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASE 13; MEMBRANE PROTEINS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIGHT JUNCTIONS; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 65549101374     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21746     Document Type: Article

References (52)

1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. 1997. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406-415.
2. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. 2000. Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1689.
3. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH. 2001. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732.
4. Brand T, Sharma HS, Fleischmann KE, Duncker DJ, McFalls EO, Verdouw PD, Schaper W. 1992. Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res 71:1351-1360.
5. Brinckerhoff CE, Rutter JL, Benbow U. 2000. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830.
6. Chandrasekar B, Mummidi S, Valente AJ, Patel DN, Bailey SR, Freeman GL, Hatano M, Tokuhisa T, Jensen LE. 2005. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 280:26263-26277.
7. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS. 2006. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11:1116-1125.
8. Chiu YC, Yang RS, Hsieh KH, Fong YC, Way TD, Lee TS, Wu HC, Fu WM, Tang CH. 2007. Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes. Mol Pharmacol 72:695-703.
9. Chiu YC, Huang TH, Fu WM, Yang RS, Tang CH. 2008. Ultrasound stimulates MMP-13 expression through p38 and JNK pathway in osteoblasts. J Cell Physiol 215:356-365.
10. Cserr HF, Bundgaard M. 1986. The neuronal microenvironment: A comparative view. Ann NY Acad Sci 481:1-6.
11. Eng LF, Ghirnikar RS. 1994. GFAP and astrogliosis. Brain Pathol 4:229-237.
12. Fishman RA. 1975. Brain edema. N Engl J Med 293:706-711.
13. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Oberg JO, Osterberg T. 2005. In vitro models for the blood-brain barrier. Toxicol In Vitro 19:299-334.
14. Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, Rice K, Brennan WA, Jr. 1997. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 38:2423-2427.
15. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. 1995. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120-2126.
16. Hamby ME, Uliasz TF, Hewett SJ, Hewett JA. 2006. Characterization of an improved procedure for the removal of microglia from confluent monolayers of primary astrocytes. J Neurosci Methods 150:128-137.
17. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. 1999. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624-633.
18. Huber JD, Egleton RD, Davis TP. 2001. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24:719-725.
19. Iyer S, Ferreri DM, DeCocco NC, Minnear FL, Vincent PA. 2004. VE-cadherin-p120 interaction is required for maintenance of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 286:L1143-L1153.
20. Jiang X, Namura S, Nagata I. 2001. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 305:41-44.
21. Lee SR, Tsuji K, Lee SR, Lo EH. 2004. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24:671-678.
22. Lu DY, Liou HC, Tang CH, Fu WM. 2006. Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1alpha. Biochem Pharmacol 72:992-1000.
23. Lu DY, Tang CH, Liou HC, Teng CM, Jeng KC, Kuo SC, Lee FY, Fu WM. 2007. YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. Br J Pharmacol.
24. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. 2001. Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke 32:1759-1766.
25. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. 2003. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598-603.
26. Muller JM, Krauss B, Kaltschmidt C, Baeuerle PA, Rupec RA. 1997. Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. J Biol Chem 272:23435-23439.
27. Nagel S, Sandy JD, Meyding-Lamade U, Schwark C, Bartsch JW, Wagner S. 2005. Focal cerebral ischemia induces changes in both MMP-13 and aggrecan around individual neurons. Brain Res 1056:43-50.
28. O'Callaghan JP, Miller DB, Reinhard JF, Jr. 1990. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 521:73-80.
29. Piacentini L, Karliner JS. 1999. Altered gene expression during hypoxia and reoxygenation of the heart. Pharmacol Ther 83:21-37.
30. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E. 1996. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 16:488-496.
31. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. 1998. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020-1030.
32. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J. 2005. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415-1420.
33. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. 1992. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576:203-207.
34. Rosenberg GA, Dencoff JE, Correa N, Jr., Reiners M, Ford CC. 1996a. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology 46:1626-1632.
35. Rosenberg GA, Navratil M, Barone F, Feuerstein G. 1996b. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360-366.
36. Rosenberg GA, Estrada EY, Dencoff JE. 1998. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189-2195.
37. Rupec RA, Baeuerle PA. 1995. The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. Eur J Biochem 234:632-640.
38. Sole S, Petegnief V, Gorina R, Chamorro A, Planas AM. 2004. Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol 63:338-349.
39. Spinale FG. 2002. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 90:520-530.
40. Staddon JM, Rubin LL. 1996. Cell adhesion, cell junctions and the blood-brain barrier. Curr Opin Neurobiol 6:622-627.
41. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z. 2004. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 131:5883-5895.
42. Tejima E, Zhao BQ, Tsuji K, Rosell A, van Leyen K, Gonzalez RG, Montaner J, Wang X, Lo EH. 2007. Astrocytic induction ofmatrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab 27:460-468.
43. Tromp G, Gatalica Z, Skunca M, Berguer R, Siegel T, Kline RA, Kuivaniemi H. 2004. Elevated expression of matrix metalloproteinase-13 in abdominal aortic aneurysms. Ann Vasc Surg 18:414-420.
44. Vajner L, Vytasek R, Lachmanova V, Uhlik J, Konradova V, Novotna J, Hampl V, Herget J. 2006. Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 87:383-391.
45. Vincenti MP. 2001. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 151:121-148.
46. Wagner S, Tagaya M, Koziol JA, Quaranta V, del Zoppo GJ. 1997. Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integrin alpha 6 beta 4 during focal cerebral ischemia/reperfusion. Stroke 28:858-865.
47. Watson PM, Anderson JM, Vanltallie CM, Doctrow SR. 1991. The tight-junction-specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 129:6-10.
48. Webster KA, Discher DJ, Bishopric NH. 1993. Induction and nuclear accumulation of fos and jun proto-oncogenes in hypoxic cardiac myocytes. J Biol Chem 268:16852-16858.
49. Westermarck J, Kahari VM. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781-792.
50. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. 2007. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697-709.
51. Yeh WL, Lu DY, Lin CJ, Liou HC, Fu WM. 2007. Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression. Mol Pharmacol 72:440-449.
52. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.